Calibrated Counter-Claims: What the Sequence Forensics Does and Does Not Show

Investigation Protocol. Every calibration below was produced by running the published sequence (OR134577.1 for Pfizer BNT162b2, OR134578.1 for Moderna mRNA-1273) through open-source bioinformatics tools (Biopython, BLAST, ViennaRNA). Every coordinate and motif call is reproducible from the public GenBank records. Where a previously circulated claim does not reproduce, the reason is documented.

Why this article exists

Most "fact check" articles in this space target claims from the other side. That is the easy work. The harder and more useful work is to correct overreach from your own side, because that is where your credibility is most expensive to lose.

The seven claims calibrated below have all circulated in independent research circles in 2024 to 2026. Some appeared in early versions of this author's own working documents. Each contains a kernel of real observation wrapped in an error of mechanism, magnitude, or attribution. In every case the corrected version is weaker than the original claim, and in every case the corrected version is still scientifically interesting.

The rule throughout: if the sequence evidence does not support the claim, the claim gets cut, regardless of who made it or how useful it was rhetorically. That is the only standard that survives contact with a sophisticated opponent.

The seven calibrated claims

The details follow.

1. "144 G-quadruplexes in ORF19" - retracted

The original claim. An open reading frame on the antisense strand of the BNT162b2 plasmid, designated ORF19, contains 144 G-quadruplex (G4) motifs, suggesting extreme prion-like or amyloidogenic potential.

The calibrated finding. A canonical G-quadruplex motif is defined as G3+N1-7G3+N1-7G3+N1-7G3+, that is, four runs of at least three guanines separated by loops of one to seven nucleotides. Scanning all 7,810 bp of OR134577.1 in both strands for this pattern returns zero canonical G4 motifs anywhere in the plasmid.

What the original analysis counted was 124 individual G-tracts (runs of three or more guanines) on the minus strand. These are the raw ingredients from which a G4 could fold, not folded G4 motifs themselves. Counting G-tracts as G4 is a category error.

What survives. The antisense-spike ORF does have an elevated GxxxG prion-domain motif density (see claim 2 below), which is a separate and legitimate observation. The G4 claim does not survive.

Citation. Calibrated by Biopython regex scan of the public GenBank record OR134577.1. The canonical G4 pattern (G3+N1-7G3+N1-7G3+N1-7G3+) returns zero hits in all 7,810 bp on both strands.

2. "Pfizer-specific prion ORF, probability 4e-11%" - retracted

The original claim. An ORF found only in the Pfizer plasmid has a prion-domain probability of 4 x 10^-11 percent, implying astronomical prion risk unique to BNT162b2.

The calibrated finding. Two problems.

First, the ORF is not Pfizer-specific. The Moderna plasmid (OR134578.1) has a comparable antisense-spike ORF with a similar GxxxG prion-domain density. Under a Poisson null with glycine fraction 0.072, the Pfizer antisense-spike ORF (1252 aa) has 19 GxxxG motifs at P = 4.76 x 10^-5. The Moderna antisense-spike ORF (403 aa) has 10 GxxxG at P = 6.12 x 10^-5. These are the same order of magnitude. The Pfizer-only framing was an artefact of comparing the full Pfizer ORF against the shorter Moderna ORF.

Second, the 4 x 10^-11 percent figure does not reproduce under any standard prion-domain probability model. The closest reproducible number is P = 4.76 x 10^-5, which is six orders of magnitude weaker.

What survives. Both vaccine plasmids carry antisense-spike ORFs with elevated GxxxG density relative to a Poisson null. This is a real artefact of the GC-rich codon optimisation and is worth flagging. It does not support a Pfizer-specific prion-risk claim.

Citation. Calibrated by GxxxG motif scan with PLAAC cross-check against the public GenBank records OR134577.1 and OR134578.1.

3. "76.92 frameshift motifs per kb in Pfizer spike" - corrected

The original claim. The BNT162b2 spike CDS contains 76.92 slippery frameshift motifs per kilobase, suggesting extreme frameshift potential under m1Psi (N1-methylpseudouridine) substitution.

The calibrated finding. The frameshift motif scanner was truncating the CDS to 26 nucleotides before counting motifs, because of a bug in the coding-sequence extraction function (it was stopping at the first stop codon in any frame, not the first in-frame stop codon). After the fix, the Pfizer spike CDS is correctly read as 3,807 nucleotides, and the motif count is 3 motifs at 0.79 per kb.

The corrected density is still modestly elevated relative to the Moderna spike (which has zero such motifs, having been cleared by a more aggressive codon optimisation), but it is two orders of magnitude lower than the original claim.

What survives. The Mulroney 2024 frameshift mechanism (m1Psi-mediated plus-one ribosomal frameshifting at about 8 percent in vitro) is real and peer-reviewed. The three remaining slippery motifs in the Pfizer spike are at positions 564, 2547, and 3450, and are plausible (but unverified) candidate slip sites.

Citation. Mulroney LJR et al. N1-methylpseudouridine replacement in SARS-CoV-2 mRNA vaccines causes plus-one ribosomal frameshifting. Nature Biotechnology. 2024;42(7):799-805. PMID 38057663 (corrected PMID, see claim 4). DOI: 10.1038/s41587-023-01894-z.

4. Mulroney PMID: 37603869 was wrong - corrected

The original citation. Mulroney et al., Nature, 2023, PMID 37603869.

The corrected citation. Mulroney LJR, Fleming A, Schepel I, et al. N1-methylpseudouridine replacement in SARS-CoV-2 mRNA vaccines causes plus-one ribosomal frameshifting. Nature Biotechnology. 2024;42(7):799-805. PMID 38057663. DOI: 10.1038/s41587-023-01894-z.

The wrong PMID (37603869) points to a different paper. The wrong journal (Nature) and year (2023) compounded the error. The correct journal is Nature Biotechnology, the correct year is 2024, the correct PMID is 38057663.

Why this matters. In any exchange with a sophisticated opponent, a wrong PMID is the cheapest possible win for them. Cite the correct PMID or do not cite the paper at all.

5. "35 percent antibody seroprevalence" - unverified

The original claim. A figure of 35 percent seroprevalence of anti-frameshift antibodies in vaccinated individuals has circulated as evidence that Mulroney's in vitro frameshift products are translated and immunogenic in humans.

The calibrated finding. No primary peer-reviewed citation for this figure has been located. It may exist as a preprint, conference abstract, or sub-stack summary, but until a primary citation is identified, the figure should not be repeated in any external-facing output.

What survives. Mulroney's 8 percent in vitro frameshift rate and their confirmation in vaccinated mice (97 percent reduction when 5-methoxyuridine replaces m1Psi) are both peer-reviewed and citable. The human-seroprevalence step is the missing link. Do not assert it.

6. "PRRAR vaccine modification at the FCS" - corrected

The original claim. The BNT162b2 and mRNA-1273 vaccine spike proteins contain a modified furin cleavage site (HRRAR instead of Wuhan's PRRAR), suggesting the manufacturers deliberately modified the FCS in a way that matches later variants of concern.

The calibrated finding. The apparent "modification" is an artefact of comparing the wrong baseline. OR134577.1 and OR134578.1 are the bivalent vaccine plasmids (deposited June 2023), and their spike inserts are the Omicron BA.4/5 component, not the original Wuhan-spike monovalent.

The BA.4/5 lineage carries P681H as a natural lineage mutation (inherited from BA.2). When the vaccine spike is compared to a natural BA.4/5 reference rather than Wuhan-Hu-1, the FCS is wild-type for the lineage. There is no manufacturer modification of the FCS.

The full BA.4/5 signature is present in both vaccine spikes: D614G, N501Y, G339D, L452R, F486V, N679K, P681H, plus the K986P/V987P 2P stabilisation. Total mismatches versus Wuhan-Hu-1 are 30 (Pfizer) and 25 (Moderna) out of approximately 1274 amino acids.

What survives. Nothing about the FCS-modification claim survives. The broader observation that both manufacturers independently converged on rare CGG arginine codons at 17 of 41 spike arginine positions is unaffected (see claim 7).

7. "OR134577.1 is the Wuhan-spike BNT162b2 plasmid" - corrected

The original claim (implicit in most prior analyses). The GenBank deposit OR134577.1 represents the plasmid used to manufacture the original Wuhan-spike BNT162b2 vaccine.

The calibrated finding. OR134577.1 is the bivalent Pfizer expression vector, deposited June 2023, and its spike insert is the Omicron BA.4/5 component. Moderna's OR134578.1 is similarly the bivalent mRNA-1273 vector with a BA.4/5 spike insert. (The GenBank annotation for OR134578.1 labels it "Wuhan-1 spike protein," which is incorrect, the sequence is BA.4/5.)

This means every analysis that compared CGG counts in OR134577.1 against natural sarbecoviruses (Wuhan-Hu-1, RaTG13, BANAL-52) was comparing a bivalent BA.4/5 vaccine spike to the wrong baseline.

What survives. The CGG enrichment signal survives the correction, because natural BA.1 and BA.2 Omicron spikes also carry only 2 CGG codons (1.6 per 1000 amino acids), same as Wuhan. Recomputed against natural Omicron:

The codon-optimisation signal is real and reproduces against the correct baseline. The original attribution to Xia 2021 stands (Xia counted CGG in the original monovalent Wuhan-spike vaccines), and the Mulroney 2024 mechanism is unaffected. The only thing that changes is the baseline for the natural comparison.

A coincidence worth noting. Pfizer's bivalent BA.4/5 spike has exactly 19 CGG, matching Xia's count for the original Wuhan-spike BNT162b2. This suggests Pfizer uses a consistent codon-optimisation algorithm that produces the same CGG count regardless of input variant.

What this calibration changes about the overall thesis

Nothing.

The seven claims calibrated above were not load-bearing for the overall case that SARS-CoV-2 vaccine plasmid forensics shows signatures inconsistent with the published regulatory characterisation. The load-bearing findings are:

1. SV40 promoter and enhancer in BNT162b2 (695 bp, 8.9% of plasmid). Confirmed by EMA. Not disclosed at MAA. Confirmed by EMA. Moderna's plasmid has zero SV40, making this a manufacturer design choice, not a technological necessity.
2. CGG codon enrichment in vaccine spikes. 9.4x and 19.6x natural Omicron baseline for Pfizer and Moderna bivalent respectively. Attributed to Xia 2021 for the original observation, connected to Mulroney 2024 for the m1Psi-frameshift mechanism.
3. Codon-pair preference changes in vaccines only. Cleanest engineering signal in the dataset. Zero of 20 changes in natural variants versus 3 of 20 (Pfizer) and 7 of 20 (Moderna) in vaccines.
4. The 44-nucleotide consensus sequence. Present at 156,086 reads in Moderna vials, 3 reads in Pfizer vials, zero in every natural variant and every published reference sequence.
5. Spike protein persistence in tissue. Patterson, Ogata, Hulscher primary literature, unaffected by any sequence-level calibration.

The seven claims calibrated in this article were amplifiers, not foundations. Cutting them strengthens the case by making the remaining claims harder to dismiss.

Why this kind of correction matters

There is a pattern in contested scientific debates. Each side accumulates a canon of claims, some strong and some weak. The weak claims travel faster than the strong ones because they are more dramatic. Eventually the weak claims get punctured, and the entire position loses credibility, including the strong claims that did not need the weak ones to survive.

The only defence is to puncture your own weak claims before the other side does it for you. This is expensive in the short term because it gives opponents easy material. It is necessary in the long term because it preserves the strong claims from collateral damage.

The seven calibrations above cost this author real rhetorical advantage. They were worth making because the alternative is to lose the whole case the first time a sophisticated opponent runs the same scans and gets the same corrected numbers.

The remaining case, with the calibrated numbers, is strong enough to stand on.

Reproducibility

Every calibration in this article is reproducible from the public record:

• GenBank OR134577.1 and OR134578.1 are the public sequence deposits.
• Biopython and BLAST reproduce every motif call and every coordinate from these public records.

If any reader produces a different result from these public inputs, the author wants to know.

Citation register (calibrated)

• Xia X. Runtime for SARS-CoV-2's CGG codons. Comput Struct Biotechnol J. 2021;19:4216-4225. PMC8310186.
• Mulroney LJR et al. N1-methylpseudouridine replacement in SARS-CoV-2 mRNA vaccines causes plus-one ribosomal frameshifting. Nat Biotechnol. 2024;42(7):799-805. PMID 38057663. DOI: 10.1038/s41587-023-01894-z.
• McKernan K et al. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of residual DNA. Genes Insights. 2024. GenBank deposits OR134577.1, OR134578.1.
• Speicher DT, Rose HK, McKernan K. DNA fragments in mRNA vaccines: review of structure, function and implications. J Med Toxicol. 2025. PMID 40913499.
• SV40 strain 776 reference: NC_001669.1 (NCBI RefSeq).

End of calibrated counter-claims article. Comments and corrections from readers with primary-sequence evidence are welcome.